首页> 外文OA文献 >Randomized controlled clinical study comparing a volume-stable collagen matrix to autogenous connective tissue grafts for soft tissue augmentation at implant sites: linear volumetric soft tissue changes up to 3 months
【2h】

Randomized controlled clinical study comparing a volume-stable collagen matrix to autogenous connective tissue grafts for soft tissue augmentation at implant sites: linear volumetric soft tissue changes up to 3 months

机译:比较体积稳定的胶原蛋白基质与自体结缔组织移植物以在植入部位增强软组织的随机对照临床研究:线性体积软组织变化长达3个月

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

AIM: To test whether or not the use of a volume-stable collagen matrix (VCMX) results in soft tissue volume increase at implant sites non-inferior to an autogenous subepithelial connective tissue graft (SCTG).\udMETHODS: In 20 patients, soft tissue augmentation at implant sites was performed using VCMX or SCTG. Casts obtained prior to augmentation (BL), at 30 (FU-30) and 90 days (FU-90) were digitized and transferred to stereolithography (STL) files. BL, FU-30 and FU-90 STL files were superimposed and linear volumetric changes evaluated in crestal and buccal regions of interest (ROI). Descriptive analysis was computed for both groups and a test for non-inferiority was performed.\udRESULTS: The median linear changes from BL to FU-90 in the crestal ROI amounted to 0.175 mm (0.06; 0.51) for VCMX (p = 0.002 over time) and to 0.51 mm (0.23; 0.94) for SCTG (p = 0.129). The differences between the two groups were not significant (p = 0.287). The respective values in the buccal ROI were 0.59 mm (0.26; 1.06) for VCMX (p = 0.002) and 0.94 mm (0.66; 1.13) for SCTG (p = 0.004). The differences between the two groups were not significant (crestal: p = 0.287; buccal: p = 0.534). Non-inferiority could be concluded for VCMX compared to SCTG for both ROI.\udCONCLUSION: VCMX and SCTG can be used for soft tissue augmentation at implant sites resulting in an at least short-term increase in volume.
机译:目的:测试使用体积稳定的胶原蛋白基质(VCMX)是否会导致不低于自体上皮下结缔组织移植物(SCTG)的植入部位的软组织体积增加。\ udMETHODS:在20例患者中,软使用VCMX或SCTG进行植入部位的组织扩增。在增强(BL),30(FU-30)和90天(FU-90)之前获得的铸件被数字化并传输到立体光刻(STL)文件中。叠加BL,FU-30和FU-90 STL文件,并在感兴趣的颊部和颊部区域(ROI)评估线性体积变化。两组都进行了描述性分析,并进行了非劣效性测试。\ ud结果:VCMX的最高ROI中从BL到FU-90的中值线性变化总计为0.175 mm(0.06; 0.51)(p = 0.002以上)时间),对于SCTG(p = 0.129)为0.51毫米(0.23; 0.94)。两组之间的差异不显着(p = 0.287)。对于VCMX(p = 0.002),颊侧ROI的相应值为0.59 mm(0.26; 1.06);对于SCTG(p = 0.004),颊侧ROI的相应值为0.94 mm(0.66; 1.13)。两组之间的差异不显着(最高:p = 0.287;颊部:p = 0.534)。结论:VCMX和SCTG可用于植入部位的软组织增强,从而至少在短期内增加体积,因此可以得出VCMX与SCTG相比非劣效性的结论。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号